90 results
8-K
EX-99.1
APVO
Aptevo Therapeutics Inc
5 Mar 24
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
8:15am
liabilities:
Accounts payable and other accrued liabilities
Accrued compensation
Current portion of long-term debt
Other current liabilities
Total current … liabilities
Long-term debt
Operating lease liability
Total liabilities
Stockholders' equity:
Preferred stock: $0.001 par value; 15,000,000 shares
DEFR14A
APVO
Aptevo Therapeutics Inc
16 Jan 24
Revised proxy
4:15pm
common stock in the short- and long-term;
our ability to maintain our listing on The Nasdaq Capital Market;
which Reverse Stock Split ratio would … , we cannot assure you that, if implemented, our common stock will be more attractive to institutional and other long-term investors. Even if we
8-K
EX-99.1
h6d1q 0jl0tpmpu
14 Nov 23
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
12:00am
8-K
EX-99.1
me3tr7rt0ke22v9
10 Aug 23
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
8:16am
8-K
EX-99.1
9blu qws6he
11 May 23
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
8:15am
8-K
EX-99.1
wil8ky 1n
30 Mar 23
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
7:50am
8-K
EX-99.1
u5h7tvi csbb5p2r9j68
10 Nov 22
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
8:15am
8-K
EX-99.1
6szpabz
11 Aug 22
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
8:15am